GH Research PLC Ordinary Shares (NASDAQ: GHRS)
$8.9250
-0.0550 ( -0.83% ) 35.0K
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Market Data
Open
$8.9250
Previous close
$8.9800
Volume
35.0K
Market cap
$467.21M
Day range
$8.3950 - $9.1500
52 week range
$5.5000 - $14.9900
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Form 6-K | 1 | Dec 05, 2024 |
| 6-k | Form 6-K | 75 | Nov 14, 2024 |
| 6-k | Form 6-K | 12 | Sep 20, 2024 |
| 6-k | Form 6-K | 1 | Sep 16, 2024 |
| 6-k | Form 6-K | 1 | Sep 09, 2024 |
| 6-k | Form 6-K | 59 | Sep 03, 2024 |
| 6-k | Form 6-K | 37 | Sep 03, 2024 |
| 6-k | Form 6-K | 1 | Sep 03, 2024 |
| 6-k | Form 6-K | 1 | Jun 28, 2024 |